A comparison of the long-term durability of nevirapine, efavirenz and lopinavir in routine clinical practice in Europe: a EuroSIDA study
| Autor: | Reekie, J., Begovac, Josip |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2011 |
| Předmět: |
Argentina/epidemiology
benzoxazines/adverse effects/ therapeutic use drug administration schedule drug resistance drug therapy combination Europe/epidemiology female HIV fnfections/ drug therapy/epidemiology/virology HIV Protease Inhibitors/ therapeutic use Hiv-1 humans Israel/epidemiology lopinavir male nevirapine/adverse effects/ therapeutic use immune system diseases virus diseases |
| Popis: | The durability of combination antiretroviral therapy (cART) regimens can be measured as time to discontinuation because of toxicity or treatment failure, development of clinical disease or serious long-term adverse events. The aim of this analysis was to compare the durability of nevirapine, efavirenz and lopinavir regimens based on these measures. Patients starting a nevirapine, efavirenz or lopinavir-based cART regimen for the first time after 1 January 2000 were included in the analysis. Follow-up started >= 3 months after initiation of treatment if viral load was < 500 HIV-1 RNA copies/mL. Durability was measured as discontinuation rate or development/worsening of clinical markers. RA total of 603 patients (21%) started nevirapine-based cART, 1465 (51%) efavirenz, and 818 (28%) lopinavir. After adjustment there was no significant difference in the risk of discontinuation for any reason between the groups on nevirapine and efavirenz (P=0.43) or lopinavir (P=0.13). Compared with the nevirapine group, those on efavirenz had a 48% (P=0.0002) and those on lopinavir a 63% (P < 0.0001) lower risk of discontinuation because of treatment failure and a 31% (P=0.01) and 66% (P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|